Abstract
The Expert Council for Tofacitinib (TOFA) and two symposiums on New Possibilities for Targeted Therapy of Rheumatoid Arthritis and on Success Factor of Biological Therapy for Rheumatic Diseases were held within the annual scientific-and-practical conference of the V.A. Nasonova Research Institute of Rheumatology on Comorbidity in Rheumatic Diseases in Moscow on 14–15 October 2014.
Highlights
on Success Factor of Biological Therapy for Rheumatic Diseases were held within the annual scientific-and-practical conference of the V.A
B. Combe (Франция) в докладе «Результаты долгосрочной безопасности применения тофацитиниба: обзор программ длительного наблюдения и реальная практика» представил новые данные о длительном применении ТОФА в рамках продленной фазы клинических исследований (LTE) и в реальной практике
Summary
Hot topics in modern rheumatology The Expert Council for Tofacitinib (TOFA) and two symposiums on New Possibilities for Targeted Therapy of Rheumatoid Arthritis and on Success Factor of Biological Therapy for Rheumatic Diseases were held within the annual scientific-and-practical conference of the V.A. В исследованиях 3-й фазы частота серьезных ССС составила 0,44 и 0,66 на 100 пациентов-лет для доз ТО- В исследовании LTE частота ССС оставалась низкой (0,19 и 0,23 на 100 пациентов-лет для доз ТОФА 5 мг 2 раза в день и 10 мг 2 раза в день соответственно), накопление риска со временем отсутствовало.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
